眼部护理

See how the invention of the first antihistamine eye drops sparked a journey of discovery focused on challenging eye diseases.

\r\n"}}" id="text-6c7a46d481" class="cmp-text">

看到第一个抗组胺剂滴眼液的发明引发了一场探索之旅集中在具有挑战性的眼疾。

建筑遗产的保护和保护视力

Blindness and vision loss impact over 1 billion people around the world. From our first discovery in 1948 at Allergan, now part of AbbVie, our scientists have pioneered research on ocular diseases and treatment for the front and back of the eye. Today we're building on our already broad and diverse portfolio with a focus on neurodegenerative diseases of the retina and ocular surface diseases. We're investigating the genetic basis for certain diseases to help us bring forward innovative medicines to reduce the treatment burden for patients.

\r\n"}}" id="text-be0a46a87d" class="cmp-text">

失明和视力丧失的影响超过10亿个世界各地的人们。从1948年第一次发现爱力根,现在AbbVie的一部分,我们的科学家已率先在眼部疾病的研究和治疗眼睛的正面和背面。今天我们构建我们已经广泛和多样化的投资组合集中在视网膜神经退行性疾病和眼表疾病。我们调查某些疾病的遗传基础来帮助我们提出创新药物,以减少病人的治疗负担。


虽然没有剧本的先锋,我们必须继续针对未满足的需求。

迈克·罗宾逊,医学博士
副总裁、临床发展,眼科,A狗万正网地址bbVie
AbbVie眼部护理科学家专注于挑战眼疾和提高护理水平的机会。

研究兴趣

Each year more people will receive a vision-threatening diagnosis due to aging and lifestyle factors. Our robust research and development approach is anchored in improving the standards of care across multiple disease areas to make a meaningful difference for patients.
\r\n
\r\nOur research, focused on unmet needs, fuels an innovative pipeline of treatments that seek to preserve and protect vision and prevent blindness. Our research interests include:

\r\n

Improving standards for all
\r\nBridging our understanding of biological processes and the genetic basis of human disease to accelerate ophthalmic drug discovery.
\r\n
\r\nFinding new approaches
\r\nLeading innovation in long-acting therapeutic approaches via mechanism of action, sustained-release formulations or gene therapy to reduce the treatment burden.
\r\n
\r\nCollaboration in innovation
\r\nWorking with colleagues across AbbVie to seize the scientific opportunity of innovation within oncology, immunology and neuroscience through knowledge of common disease pathways.
\r\n
\r\nState-of-the-art imagery
\r\nApplying state-of-the-art imaging modalities to monitor disease progression and therapeutic intervention to accelerate the translation of bench science to the clinic.
\r\n
\r\nStrategic collaboration
\r\nJoining forces with innovative partners that complement our strengths, capabilities and commitments to eye care, including our work in chronic retinal diseases with REGENXBIO.

\r\n"}}" id="text-16b65ce828" class="cmp-text">

每年有更多的人将获得该诊断由于老化和生活方式因素。我们强大的研究和开发方法是固定在改善跨多个疾病护狗万正网地址理领域的标准对病人做出有意义的差别。

我们的研究,关注未满足的需求,燃料创新型管道的治疗寻求保护,保护视力,防止失明。我们的研究兴趣包括:

提高标准,适用于所有
桥接我们理解生物过程和人类疾病的遗传基础,加快眼科药物发现。

寻找新方法
领先创新长效治疗方法通过作用机理、缓释配方或基因疗法来减少治疗的负担。

合作创新
与同事工作在AbbVie抓住科学创新的机会在肿瘤学,免疫学和神经科学知识常见疾病的途径。

先进的图像
应用先进的成像技术来监测疾病进展和治疗干预,加快长椅上科学的翻译到诊所。

战略协作
联合创新的伙伴,补充我们的优势,眼部护理能力和承诺,包括我们的工作与REGENXBIO慢性视网膜疾病。

疾病的迹象

We are focused on some of the most challenging eye diseases, including:

\r\n"}}" id="text-81c6841e14" class="cmp-text">

我们专注于一些最具挑战性的眼疾,包括:


眼保健重点领域

想成为一个尖端的眼部护理团队的一部分吗?

Explore our career opportunities.

\r\n"}}" id="text-bbf9018e8b" class="cmp-text">

探索我们的职业机会。